Abstract：
OBJECTIVE: Sinonasal metastases arising from renal cell cancer are rare and usually managed with surgery. Few studies describe the use of radiotherapy in this specific setting, while the use of stereotactic body radiotherapy (SBRT) has been rarely reported as well.
METHODS: We present the case of a solitary left sinonasal metastasis in a 65-year-old man with clear cell renal cancer who also received bilateral nephrectomy and subsequent kidney transplantation. The patient received subtotal surgery and subsequently he was candidate to SBRT to avoid systemic treatment, due to renal comorbidities.
CONCLUSIONS: The patient was treated with SBRT for a total dose of 35 Gy in 5 fractions and after 24 months of follow-up there is no evidence of local relapse. No major side-effects were reported. Our experience supports SBRT as a safe and feasible treatment option in the case of sinonasal metastases from RCC.
METHODS: We present the case of a solitary left sinonasal metastasis in a 65-year-old man with clear cell renal cancer who also received bilateral nephrectomy and subsequent kidney transplantation. The patient received subtotal surgery and subsequently he was candidate to SBRT to avoid systemic treatment, due to renal comorbidities.
CONCLUSIONS: The patient was treated with SBRT for a total dose of 35 Gy in 5 fractions and after 24 months of follow-up there is no evidence of local relapse. No major side-effects were reported. Our experience supports SBRT as a safe and feasible treatment option in the case of sinonasal metastases from RCC.
摘要：
目的：肾细胞癌引起的鼻窦转移很少见，通常通过手术治疗。很少有研究描述在这种特定环境中使用放射治疗，而立体定向放疗（SBRT）的使用也很少报道。
方法：我们介绍了一名65岁的男性透明细胞肾癌患者的孤立性左鼻窦转移病例，该患者还接受了双侧肾切除术和随后的肾移植。患者接受了大部手术，随后他是SBRT的候选人，以避免全身治疗。由于肾脏合并症。
结论：患者接受SBRT治疗，总剂量为35Gy，分5次，随访24个月后，没有局部复发的证据。没有报告重大副作用。我们的经验支持SBRT作为RCC鼻窦转移的安全可行的治疗选择。
方法：我们介绍了一名65岁的男性透明细胞肾癌患者的孤立性左鼻窦转移病例，该患者还接受了双侧肾切除术和随后的肾移植。患者接受了大部手术，随后他是SBRT的候选人，以避免全身治疗。由于肾脏合并症。
结论：患者接受SBRT治疗，总剂量为35Gy，分5次，随访24个月后，没有局部复发的证据。没有报告重大副作用。我们的经验支持SBRT作为RCC鼻窦转移的安全可行的治疗选择。
